2.1K(top 0.1%)
papers
68.3K(top 0.1%)
citations
126(top 0.1%)
h-index
218(top 0.1%)
g-index
2.2K
all documents
72.8K
doc citations
5.1K
citing journals
925
times ranked

Top Articles

#TitleJournalYearCitations
1Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT RecommendationsJournal of Pain20082,564
2Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncology, The20092,404
3SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinaseProceedings of the National Academy of Sciences of the United States of America20012,350
4Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood20171,173
5International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood2015982
6The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer2004731
7Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialLancet Oncology, The2013710
8Rhinosinusitis: Establishing definitions for clinical research and patient careJournal of Allergy and Clinical Immunology2004705
9Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia2012668
10Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSNature2015648
11Microbial species delineation using whole genome sequencesNucleic Acids Research2015609
12Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T CellsScience Translational Medicine2012555
13Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alphaJournal of Immunology1999553
14Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-αJournal of Immunology1999542
15Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsLeukemia2001536
16Enantioselective Catalytic Formation of Quaternary Stereogenic CentersEuropean Journal of Organic Chemistry2007523
17Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology2014505
18Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Journal of the American Academy of Dermatology2015498
19Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel DiseaseCell2018454
20A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qBlood2011424
21A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligaseNature2016414
22Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple MyelomaJAMA Oncology2017405
23Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor CellsClinical Cancer Research2008401
24Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)British Journal of Dermatology2015384
25Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogsNature Structural and Molecular Biology2014383
26Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnnals of the Rheumatic Diseases2014372
27The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsCancer Immunology, Immunotherapy2009362
28Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia2009350
29Apremilast mechanism of action and application to psoriasis and psoriatic arthritisBiochemical Pharmacology2012346
30Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology2010344
31Nrf2: A Potential Molecular Target for Cancer Chemoprevention by Natural CompoundsAntioxidants and Redox Signaling2006337
32Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBlood2018335
33Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesNew England Journal of Medicine2020335
34Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α productionBioorganic and Medicinal Chemistry Letters1999331
35Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisHaematologica2018329
36Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood2014327
37A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisLeukemia2019313
38Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest GroupValue in Health2015311
39A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLoS ONE2010310
40Development of targeted protein degradation therapeuticsNature Chemical Biology2019303
41Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical responseBlood2017300
42Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseasesNature Genetics2020298
43The standard operating procedure of the DOE-JGI Microbial Genome Annotation Pipeline (MGAP v.4)Standards in Genomic Sciences2015287
44Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effectsBritish Journal of Cancer2002280
45AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJournal of Clinical Oncology2019277
46A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in Sprague–Dawley ratsToxicology2002265
47Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision AnalysisJournal of Clinical Oncology2013265
48Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenibBlood2019262
49Trends in overall survival and costs of multiple myeloma, 2000–2014Leukemia2017257
50Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialLancet Oncology, The2019254